Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

clopidogrel (Plavix), bivalirudin (Angiomax), and abciximab (ReoPro), and was the first physician to raise safety concerns about rofecoxib (Vioxx). He has published 1100 peer-reviewed articles and ...

US President Donald Trump criticized $21 million funding for voter turnout in India and $29 million to strengthen Bangladesh's political landscape. He questioned the allocation of such substantial ...

Feb. 3, 2025 — Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the ...

Feb. 19, 2025 — Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could ...

The legal onslaught on Moscow’s second-largest airport has been seen as part of the Kremlin’s wartime drive to seize control of key assets still in private hands. By Nataliya Vasilyeva A ...

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. The field of ...

Hamas said it handed over four hostages to Israel in a display a senior U.N. official called “abhorrent and cruel.” Israel later said only three bodies belonged to captives. By Aaron ...

Herzog thanked the Roman Jewish community for their support and solidarity with the Israeli people and addressed their deep concerns for the difficult days ahead. Information ...

Leading progressive Canadian journalists respond to Trump’s tariff threats, offering insight into how the trade spat is reshaping Canadian politics and US-Canada relations. In spite of the ...

Sixteen years ago, we launched the ArchDaily Building of the Year Awards with a simple yet powerful idea: to let our readers choose their favorite buildings from our ever-growing library of ...